Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition
Glitazones are peroxisome proliferator-activated receptor gamma (PPARγ) agonists widely used as antidiabetic drugs also known as thiazolidinediones. Most of them exert other effects such as anti-inflammatory actions via mechanisms supposed to be independent from PPARγ activation (e.g., decreased pla...
Gespeichert in:
Veröffentlicht in: | Journal of physiology and biochemistry 2015-09, Vol.71 (3), p.487-496 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 496 |
---|---|
container_issue | 3 |
container_start_page | 487 |
container_title | Journal of physiology and biochemistry |
container_volume | 71 |
creator | Carpéné, Christian Bizou, Mathilde Tréguer, Karine Hasnaoui, Mounia Grès, Sandra |
description | Glitazones are peroxisome proliferator-activated receptor gamma (PPARγ) agonists widely used as antidiabetic drugs also known as thiazolidinediones. Most of them exert other effects such as anti-inflammatory actions via mechanisms supposed to be independent from PPARγ activation (e.g., decreased plasma monocyte chemoattractant protein-1 (MCP-1) levels). Recently, pioglitazone has been shown to inhibit the B form of monoamine oxidase (MAO) in mouse, while rosiglitazone and troglitazone were described as non-covalent inhibitors of both human MAO A and MAO B. Since molecules interacting with MAO might also inhibit semicarbazide-sensitive amine oxidase (SSAO), known as vascular adhesion protein-1 (VAP-1), and since VAP-1/SSAO inhibitors exhibit anti-inflammatory activity, our aim was to elucidate whether VAP-1/SSAO inhibition could be a mechanism involved in the anti-inflammatory behaviour of glitazones. To this aim, MAO and SSAO activities were measured in human subcutaneous adipose tissue biopsies obtained from overweight women undergoing plastic surgery. The production of hydrogen peroxide, an end-product of amine oxidase activity, was determined in tissue homogenates using a fluorometric method. The oxidation of 1 mM tyramine was inhibited by pargyline and almost resistant to semicarbazide, therefore predominantly MAO-dependent. Rosiglitazone was more potent than pioglitazone in inhibiting tyramine oxidation. By contrast, benzylamine oxidation was only abolished by semicarbazide: hence SSAO-mediated. Pioglitazone hampered SSAO activity only when tested at 1 mM while rosiglitazone was inefficient. However, rosiglitazone exhibited anti-inflammatory activity in human adipocytes by limiting MCP-1 expression. Our observations rule out any involvement of VAP-1/SSAO inhibition and subsequent limitation of leukocyte extravasation in the anti-inflammatory action of glitazones. |
doi_str_mv | 10.1007/s13105-014-0379-3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1705474142</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1705474142</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-8c39b4011cffcf00ea8d31c774c08a6a38fcc386201bc76bd9955614dc17ef6b3</originalsourceid><addsrcrecordid>eNp9kctuFDEQRS1ERF58ABvkJRsTV9vd9iyjCAJSJFiQbC23u5px1LaD7UZM_oS_xdFMkNiwqpLq1q3HIeQN8PfAubooIID3jINkXKgNEy_ICWilmFZ9_7LlIDRTvdTH5LSUe85lBx1_RY67vledkPyE_L5efLWPKWKhPm796CvdrsFGGlJMNviINP3yky1Ix7XSukWfqY3VMx_nxYZga8o7al31KRZqM9KYKg04eVtxouOO3l1-ZXBRMHhn82gf_YSsYCy--p9I_51x2KF5nZOj2S4FXx_iGbn9-OHb1Sd28-X689XlDXMSZGXaic0oOYCbZzdzjlZPApxS0nFtByv07JzQQ8dhdGoYp82m7weQkwOF8zCKM_Ju7_uQ048VSzXBF4fLYiOmtRhQvJeqzeqaFPZSl1MpGWfzkH2weWeAmyciZk_ENCLmiYgRreftwX4d21P-djwjaIJuLyitFL9jNvdpzbGd_B_XP97JmhU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1705474142</pqid></control><display><type>article</type><title>Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Carpéné, Christian ; Bizou, Mathilde ; Tréguer, Karine ; Hasnaoui, Mounia ; Grès, Sandra</creator><creatorcontrib>Carpéné, Christian ; Bizou, Mathilde ; Tréguer, Karine ; Hasnaoui, Mounia ; Grès, Sandra</creatorcontrib><description>Glitazones are peroxisome proliferator-activated receptor gamma (PPARγ) agonists widely used as antidiabetic drugs also known as thiazolidinediones. Most of them exert other effects such as anti-inflammatory actions via mechanisms supposed to be independent from PPARγ activation (e.g., decreased plasma monocyte chemoattractant protein-1 (MCP-1) levels). Recently, pioglitazone has been shown to inhibit the B form of monoamine oxidase (MAO) in mouse, while rosiglitazone and troglitazone were described as non-covalent inhibitors of both human MAO A and MAO B. Since molecules interacting with MAO might also inhibit semicarbazide-sensitive amine oxidase (SSAO), known as vascular adhesion protein-1 (VAP-1), and since VAP-1/SSAO inhibitors exhibit anti-inflammatory activity, our aim was to elucidate whether VAP-1/SSAO inhibition could be a mechanism involved in the anti-inflammatory behaviour of glitazones. To this aim, MAO and SSAO activities were measured in human subcutaneous adipose tissue biopsies obtained from overweight women undergoing plastic surgery. The production of hydrogen peroxide, an end-product of amine oxidase activity, was determined in tissue homogenates using a fluorometric method. The oxidation of 1 mM tyramine was inhibited by pargyline and almost resistant to semicarbazide, therefore predominantly MAO-dependent. Rosiglitazone was more potent than pioglitazone in inhibiting tyramine oxidation. By contrast, benzylamine oxidation was only abolished by semicarbazide: hence SSAO-mediated. Pioglitazone hampered SSAO activity only when tested at 1 mM while rosiglitazone was inefficient. However, rosiglitazone exhibited anti-inflammatory activity in human adipocytes by limiting MCP-1 expression. Our observations rule out any involvement of VAP-1/SSAO inhibition and subsequent limitation of leukocyte extravasation in the anti-inflammatory action of glitazones.</description><identifier>ISSN: 1138-7548</identifier><identifier>EISSN: 1877-8755</identifier><identifier>DOI: 10.1007/s13105-014-0379-3</identifier><identifier>PMID: 25572340</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adipocytes - drug effects ; Adipocytes - enzymology ; Adult ; Amine Oxidase (Copper-Containing) - antagonists & inhibitors ; Amine Oxidase (Copper-Containing) - metabolism ; Animal Physiology ; Anti-Inflammatory Agents - pharmacology ; Benzylamines - metabolism ; Biomedical and Life Sciences ; Biomedicine ; Cell Adhesion Molecules - antagonists & inhibitors ; Cell Adhesion Molecules - metabolism ; Drug Evaluation, Preclinical ; Female ; Human Physiology ; Humans ; Hydrogen Peroxide - metabolism ; Middle Aged ; Monoamine Oxidase Inhibitors - pharmacology ; Original Paper ; Subcutaneous Fat - drug effects ; Subcutaneous Fat - enzymology ; Subcutaneous Fat - pathology ; Thiazolidinediones - pharmacology ; Tyramine - metabolism</subject><ispartof>Journal of physiology and biochemistry, 2015-09, Vol.71 (3), p.487-496</ispartof><rights>University of Navarra 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-8c39b4011cffcf00ea8d31c774c08a6a38fcc386201bc76bd9955614dc17ef6b3</citedby><cites>FETCH-LOGICAL-c414t-8c39b4011cffcf00ea8d31c774c08a6a38fcc386201bc76bd9955614dc17ef6b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13105-014-0379-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13105-014-0379-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25572340$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carpéné, Christian</creatorcontrib><creatorcontrib>Bizou, Mathilde</creatorcontrib><creatorcontrib>Tréguer, Karine</creatorcontrib><creatorcontrib>Hasnaoui, Mounia</creatorcontrib><creatorcontrib>Grès, Sandra</creatorcontrib><title>Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition</title><title>Journal of physiology and biochemistry</title><addtitle>J Physiol Biochem</addtitle><addtitle>J Physiol Biochem</addtitle><description>Glitazones are peroxisome proliferator-activated receptor gamma (PPARγ) agonists widely used as antidiabetic drugs also known as thiazolidinediones. Most of them exert other effects such as anti-inflammatory actions via mechanisms supposed to be independent from PPARγ activation (e.g., decreased plasma monocyte chemoattractant protein-1 (MCP-1) levels). Recently, pioglitazone has been shown to inhibit the B form of monoamine oxidase (MAO) in mouse, while rosiglitazone and troglitazone were described as non-covalent inhibitors of both human MAO A and MAO B. Since molecules interacting with MAO might also inhibit semicarbazide-sensitive amine oxidase (SSAO), known as vascular adhesion protein-1 (VAP-1), and since VAP-1/SSAO inhibitors exhibit anti-inflammatory activity, our aim was to elucidate whether VAP-1/SSAO inhibition could be a mechanism involved in the anti-inflammatory behaviour of glitazones. To this aim, MAO and SSAO activities were measured in human subcutaneous adipose tissue biopsies obtained from overweight women undergoing plastic surgery. The production of hydrogen peroxide, an end-product of amine oxidase activity, was determined in tissue homogenates using a fluorometric method. The oxidation of 1 mM tyramine was inhibited by pargyline and almost resistant to semicarbazide, therefore predominantly MAO-dependent. Rosiglitazone was more potent than pioglitazone in inhibiting tyramine oxidation. By contrast, benzylamine oxidation was only abolished by semicarbazide: hence SSAO-mediated. Pioglitazone hampered SSAO activity only when tested at 1 mM while rosiglitazone was inefficient. However, rosiglitazone exhibited anti-inflammatory activity in human adipocytes by limiting MCP-1 expression. Our observations rule out any involvement of VAP-1/SSAO inhibition and subsequent limitation of leukocyte extravasation in the anti-inflammatory action of glitazones.</description><subject>Adipocytes - drug effects</subject><subject>Adipocytes - enzymology</subject><subject>Adult</subject><subject>Amine Oxidase (Copper-Containing) - antagonists & inhibitors</subject><subject>Amine Oxidase (Copper-Containing) - metabolism</subject><subject>Animal Physiology</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Benzylamines - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cell Adhesion Molecules - antagonists & inhibitors</subject><subject>Cell Adhesion Molecules - metabolism</subject><subject>Drug Evaluation, Preclinical</subject><subject>Female</subject><subject>Human Physiology</subject><subject>Humans</subject><subject>Hydrogen Peroxide - metabolism</subject><subject>Middle Aged</subject><subject>Monoamine Oxidase Inhibitors - pharmacology</subject><subject>Original Paper</subject><subject>Subcutaneous Fat - drug effects</subject><subject>Subcutaneous Fat - enzymology</subject><subject>Subcutaneous Fat - pathology</subject><subject>Thiazolidinediones - pharmacology</subject><subject>Tyramine - metabolism</subject><issn>1138-7548</issn><issn>1877-8755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctuFDEQRS1ERF58ABvkJRsTV9vd9iyjCAJSJFiQbC23u5px1LaD7UZM_oS_xdFMkNiwqpLq1q3HIeQN8PfAubooIID3jINkXKgNEy_ICWilmFZ9_7LlIDRTvdTH5LSUe85lBx1_RY67vledkPyE_L5efLWPKWKhPm796CvdrsFGGlJMNviINP3yky1Ix7XSukWfqY3VMx_nxYZga8o7al31KRZqM9KYKg04eVtxouOO3l1-ZXBRMHhn82gf_YSsYCy--p9I_51x2KF5nZOj2S4FXx_iGbn9-OHb1Sd28-X689XlDXMSZGXaic0oOYCbZzdzjlZPApxS0nFtByv07JzQQ8dhdGoYp82m7weQkwOF8zCKM_Ju7_uQ048VSzXBF4fLYiOmtRhQvJeqzeqaFPZSl1MpGWfzkH2weWeAmyciZk_ENCLmiYgRreftwX4d21P-djwjaIJuLyitFL9jNvdpzbGd_B_XP97JmhU</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Carpéné, Christian</creator><creator>Bizou, Mathilde</creator><creator>Tréguer, Karine</creator><creator>Hasnaoui, Mounia</creator><creator>Grès, Sandra</creator><general>Springer Netherlands</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150901</creationdate><title>Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition</title><author>Carpéné, Christian ; Bizou, Mathilde ; Tréguer, Karine ; Hasnaoui, Mounia ; Grès, Sandra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-8c39b4011cffcf00ea8d31c774c08a6a38fcc386201bc76bd9955614dc17ef6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adipocytes - drug effects</topic><topic>Adipocytes - enzymology</topic><topic>Adult</topic><topic>Amine Oxidase (Copper-Containing) - antagonists & inhibitors</topic><topic>Amine Oxidase (Copper-Containing) - metabolism</topic><topic>Animal Physiology</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Benzylamines - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cell Adhesion Molecules - antagonists & inhibitors</topic><topic>Cell Adhesion Molecules - metabolism</topic><topic>Drug Evaluation, Preclinical</topic><topic>Female</topic><topic>Human Physiology</topic><topic>Humans</topic><topic>Hydrogen Peroxide - metabolism</topic><topic>Middle Aged</topic><topic>Monoamine Oxidase Inhibitors - pharmacology</topic><topic>Original Paper</topic><topic>Subcutaneous Fat - drug effects</topic><topic>Subcutaneous Fat - enzymology</topic><topic>Subcutaneous Fat - pathology</topic><topic>Thiazolidinediones - pharmacology</topic><topic>Tyramine - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carpéné, Christian</creatorcontrib><creatorcontrib>Bizou, Mathilde</creatorcontrib><creatorcontrib>Tréguer, Karine</creatorcontrib><creatorcontrib>Hasnaoui, Mounia</creatorcontrib><creatorcontrib>Grès, Sandra</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of physiology and biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carpéné, Christian</au><au>Bizou, Mathilde</au><au>Tréguer, Karine</au><au>Hasnaoui, Mounia</au><au>Grès, Sandra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition</atitle><jtitle>Journal of physiology and biochemistry</jtitle><stitle>J Physiol Biochem</stitle><addtitle>J Physiol Biochem</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>71</volume><issue>3</issue><spage>487</spage><epage>496</epage><pages>487-496</pages><issn>1138-7548</issn><eissn>1877-8755</eissn><abstract>Glitazones are peroxisome proliferator-activated receptor gamma (PPARγ) agonists widely used as antidiabetic drugs also known as thiazolidinediones. Most of them exert other effects such as anti-inflammatory actions via mechanisms supposed to be independent from PPARγ activation (e.g., decreased plasma monocyte chemoattractant protein-1 (MCP-1) levels). Recently, pioglitazone has been shown to inhibit the B form of monoamine oxidase (MAO) in mouse, while rosiglitazone and troglitazone were described as non-covalent inhibitors of both human MAO A and MAO B. Since molecules interacting with MAO might also inhibit semicarbazide-sensitive amine oxidase (SSAO), known as vascular adhesion protein-1 (VAP-1), and since VAP-1/SSAO inhibitors exhibit anti-inflammatory activity, our aim was to elucidate whether VAP-1/SSAO inhibition could be a mechanism involved in the anti-inflammatory behaviour of glitazones. To this aim, MAO and SSAO activities were measured in human subcutaneous adipose tissue biopsies obtained from overweight women undergoing plastic surgery. The production of hydrogen peroxide, an end-product of amine oxidase activity, was determined in tissue homogenates using a fluorometric method. The oxidation of 1 mM tyramine was inhibited by pargyline and almost resistant to semicarbazide, therefore predominantly MAO-dependent. Rosiglitazone was more potent than pioglitazone in inhibiting tyramine oxidation. By contrast, benzylamine oxidation was only abolished by semicarbazide: hence SSAO-mediated. Pioglitazone hampered SSAO activity only when tested at 1 mM while rosiglitazone was inefficient. However, rosiglitazone exhibited anti-inflammatory activity in human adipocytes by limiting MCP-1 expression. Our observations rule out any involvement of VAP-1/SSAO inhibition and subsequent limitation of leukocyte extravasation in the anti-inflammatory action of glitazones.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>25572340</pmid><doi>10.1007/s13105-014-0379-3</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1138-7548 |
ispartof | Journal of physiology and biochemistry, 2015-09, Vol.71 (3), p.487-496 |
issn | 1138-7548 1877-8755 |
language | eng |
recordid | cdi_proquest_miscellaneous_1705474142 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Adipocytes - drug effects Adipocytes - enzymology Adult Amine Oxidase (Copper-Containing) - antagonists & inhibitors Amine Oxidase (Copper-Containing) - metabolism Animal Physiology Anti-Inflammatory Agents - pharmacology Benzylamines - metabolism Biomedical and Life Sciences Biomedicine Cell Adhesion Molecules - antagonists & inhibitors Cell Adhesion Molecules - metabolism Drug Evaluation, Preclinical Female Human Physiology Humans Hydrogen Peroxide - metabolism Middle Aged Monoamine Oxidase Inhibitors - pharmacology Original Paper Subcutaneous Fat - drug effects Subcutaneous Fat - enzymology Subcutaneous Fat - pathology Thiazolidinediones - pharmacology Tyramine - metabolism |
title | Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A09%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glitazones%20inhibit%20human%20monoamine%20oxidase%20but%20their%20anti-inflammatory%20actions%20are%20not%20mediated%20by%20VAP-1/semicarbazide-sensitive%20amine%20oxidase%20inhibition&rft.jtitle=Journal%20of%20physiology%20and%20biochemistry&rft.au=Carp%C3%A9n%C3%A9,%20Christian&rft.date=2015-09-01&rft.volume=71&rft.issue=3&rft.spage=487&rft.epage=496&rft.pages=487-496&rft.issn=1138-7548&rft.eissn=1877-8755&rft_id=info:doi/10.1007/s13105-014-0379-3&rft_dat=%3Cproquest_cross%3E1705474142%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1705474142&rft_id=info:pmid/25572340&rfr_iscdi=true |